[Skip to Navigation]
Sign In
Comment & Response
February 10, 2022

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer

Author Affiliations
  • 1Pharmacy Faculty, Pharmacology Department, University of Sevilla, Sevilla, Spain
  • 2Pharmacy Department, Hospital Universitario de Puerto Real, Puerto Real, Spain
  • 3Pharmacy Department, Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Spain
JAMA Oncol. 2022;8(4):642. doi:10.1001/jamaoncol.2021.7787

To the Editor In their randomized clinical trial published recently in JAMA Oncology, Gettinger et al1 reported that the nivolumab plus ipilimumab (N+I) regimen did not provide benefit for overall survival (OS) over nivolumab alone in immunotherapy-naive patients with pretreated advanced squamous non–small cell lung cancer (SqNSCLC). However, an OS improvement was predicted for patients with tumor PD-L1 (programmed cell death 1 ligand 1) expression less than 1% and tumor mutation burden (TMB) of 10 mutations per megabase (mt/Mb) or greater.

Add or change institution